DOCSLIB.ORG

Pharmacopoeial Reference Standards and Their Current Lot Numbers EP, EPISA, ICRS, USP, BP January 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacopoeial Reference Standards and Their Current Lot Numbers EP, EPISA, ICRS, USP, BP January 2017 Pharmacopoeial reference standards and their current lot numbers EP, EPISA, ICRS, USP, BP January 2017 Follow LGC Standards Pharma on LinkedIn Dear user, This catalogue includes all pharmacopoeial reference materials from EP, EPISA, ICRS, USP and BP available at LGC, as well as their current lot numbers. We update the catalogue on a monthly basis so that you can use the lot numbers to easily track the expiry dates of your stocked reference materials. We took the lot information from actual data from the Pharmacopoeias and correct at the time of production. We retained all spelling and information as provided by the Pharmacopoeias. The list was compiled with caution, however errors in this list may be possible, and LGC is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeia data, or from LGC during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical reference materials online at www.lgcstandards.com. Stay connected via LinkedIn (LGC Standards Pharma) or Twitter @LGCStdsPharma Kind regards Your LGC Standards Team LGC, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel.: +44 (0)20 8943 8480, Fax: +44 (0)20 8943 7554 E-Mail: [email protected] European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity 22.12.2016 EPY0001916 Teriparatide 1 1 mg New compound! EPY0001561 Abacavir sulfate 1 20 mg EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1 10 mg EPY0000055 Acamprosate calcium - reference spectrum 1 n/a EPY0000116 Acamprosate impurity A 2 110 mg EPY0000500 Acarbose 3 100 mg EPY0000354 Acarbose for identification 1 10 mg EPY0000427 Acarbose for peak identification 4 20 mg EPA0040000 Acebutolol hydrochloride 1 50 mg EPY0000359 Acebutolol impurity B 2 10 mg EPY0000127 Acebutolol impurity C 1 20 mg EPY0000128 Acebutolol impurity I 2 0.004 mg EPY0000056 Aceclofenac - reference spectrum 1 n/a EPY0000085 Aceclofenac impurity F 2 15 mg EPY0000086 Aceclofenac impurity H 1 10 mg EPY0001094 Aceclofenac for peak identification 1 10 mg EPY0000810 Acemetacin 1 100 mg EPY0000811 Acemetacin impurity A 1 10 mg EPY0000842 Acemetacin impurity mixture 1 0.06 mg EPA0070000 Acesulfame potassium 2 50 mg EPA0070020 Acesulfame potassium impurity B 4 15 mg EPA0100000 Acetazolamide 1 100 mg EPY0001084 Acetazolamide for system suitability 2 0.0068 mg EPY0000002 Acetylcholine chloride 1 50 mg EPA0150000 Acetylcysteine 3 50 mg EPA0152000 Acetylcysteine impurity C 11 10 mg EPA0153000 Acetylcysteine impurity D 7 10 mg EPY0000565 ß-Acetyldigoxin 2 50 mg EPY0000642 ß-Acetyldigoxin for peak identification 1 10 mg EPA0200000 Acetylsalicylic acid 5 10 mg Follow us on LinkedIn: https://www.linkedin.com/company/lgc-standards-pharma January 2017 and Twitter @LGCStdsPharma Pharmaceutical Lot List - NL European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001460 Acetylsalicylic acid for peak identification 3 10.3 mg EPY0001462 Acetylsulfadiazine 1 0.002 mg EPA0208000 N-Acetyltryptophan 2 125 mg EPA0202000 N-Acetyltyrosine 1 200 mg EPY0000693 Acholeplasma laidlawii BRP 1 1 ml EPA0220000 Aciclovir 3 75 mg EPY0001271 Aciclovir for peak identification 1 4 0.3 mg EPY0001269 Aciclovir for peak identification 2 4 0.004 mg EPY0001264 Aciclovir for system suitability 1 10 mg EPA0225000 Acitretin 2 100 mg EPY0001463 Actaea racemosa HRS 1 1200 mg EPY0001543 Actaea racemosa for assay CRS 1 300 mg EPY0001464 Actaea racemosa dry extract for system suitability HRS 1 1200 mg EPY0001121 Adapalene 1 100 mg EPY0001120 Adapalene impurity C 3 6 mg EPY0001119 Adapalene for peak identification 2 2.02 mg EPA0230000 Adenine 2 50 mg EPA0230200 Adenosine 1 50 mg EPY0000110 Adipic acid 1 50 mg EPY0000882 Adrenaline 1 5 mg EPY0000740 Adrenaline impurity mixture 3 0.005 mg EPY0000883 Adrenaline with impurity F 1 10 mg EPA0300000 Adrenaline tartrate 6 100 mg EPY0000707 Adrenaline tartrate with impurity A 1 15 mg EPY0001527 Aescin for LC assay HRS 1 150 mg EPY0001724 Agnus castus fruit dry extract 1 350 mg EPA0325000 Alanine 3 60 mg EPA0325100 Albendazole 2 50 mg EPA0325200 Alcuronium chloride 2 50 mg EPA0325450 Alfacalcidol 9 5 mg EPY0001601 Alfacalcidol for system suitability 1 2.5 mg Follow us on LinkedIn: https://www.linkedin.com/company/lgc-standards-pharma January 2017 and Twitter @LGCStdsPharma Pharmaceutical Lot List - NL European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPA0325451 Alfacalcidol - reference spectrum 1 n/a EPA1225000 Alfadex 3 150 mg EPA0325500 Alfentanil hydrochloride - reference spectrum 1 n/a EPY0001883 Alfuzosin for peak identification 1 10 mg EPY0000832 Alfuzosin for system suitability 1 10 mg EPY0001906 Alfuzosin for system suitability A 1 10 mg EPA0325800 Alfuzosin hydrochloride 2 10 mg EPY0001583 Alimemazine hemitartrate 1 15 mg EPY0001581 Alimemazine for system suitability 1 5 mg EPA0349000 Allantoin 1 60 mg EPA0350000 Allopurinol 3 100 mg EPA0350010 Allopurinol impurity A 2 10 mg EPA0350020 Allopurinol impurity B 3 10 mg EPA0350030 Allopurinol impurity C 3 10 mg EPA0350040 Allopurinol impurity D 4 15 mg EPA0350050 Allopurinol impurity E 1 20 mg EPA0351000 Allylstrychnine bromide 1 10 mg EPY0000235 Almagate 2 50 mg EPY0000255 Almagate - reference spectrum 1 n/a EPA0357000 Alprazolam - * psy 2 100 mg EPA0360000 Alprenolol hydrochloride 1 100 mg EPY0000054 Alprostadil 3 25 mg EPY0000606 Altizide 2 150 mg EPY0000843 Altizide impurity B 1 15 mg EPY0000687 Alverine citrate 1 5 mg EPY0001819 Alverine impurity C 2 40 mg EPY0000607 Alverine impurity D 1 10 mg EPA0363000 Amantadine hydrochloride 1 100 mg EPA0363700 Ambroxol hydrochloride 3 125 mg EPA0900000 Amfetamine sulfate - reference spectrum 1 n/a EPA0365000 Amidotrizoic acid dihydrate 1 100 mg Follow us on LinkedIn: https://www.linkedin.com/company/lgc-standards-pharma January 2017 and Twitter @LGCStdsPharma Pharmaceutical Lot List - NL European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001461 Amidotrizoic acid for system suitability 1 0.08 mg EPA0368000 Amikacin 3 200 mg EPY0001467 Amikacin impurity I 1 20 mg EPY0001117 Amikacin for system suitability 3 10 mg EPA0365900 Amikacin sulfate 3 200 mg EPA0370000 Amiloride hydrochloride 2 100 mg EPY0000020 Amiloride impurity A 3 20 mg EPY0000173 4-Aminobenzoic acid 2 60 mg EPA0420000 Aminocaproic acid 1 50 mg EPA0460000 7-Aminodesacetoxycephalosporanic acid 2 20 mg EPA0496000 Aminoglutethimide 1 125 mg EPA0496005 Aminoglutethimide impurity A 1 20 mg EPA0496020 Aminoglutethimide impurity D 1 10 mg EPA0575000 Amiodarone hydrochloride 3 100 mg EPY0000129 Amiodarone impurity D 3 20 mg EPY0000130 Amiodarone impurity E 3 20 mg EPA0590000 Amisulpride 2 10 mg EPY0001534 Amisulpride for system suitability 1 1.0015 mg EPY0000563 Amitriptyline hydrochloride 1 10 mg EPY0000049 Amlodipine besilate 4 150 mg EPY0001068 Amlodipine impurity A 3 15 mg EPY0001069 Amlodipine impurity B 3 15 mg EPY0001070 Amlodipine impurity G 3 10 mg EPY0001067 Amlodipine for peak identification 3 15 mg EPY0000302 Ammonio methacrylate copolymer(type A) - reference spectrum 1 n/a EPY0000303 Ammonio methacrylate copolymer(type B) - reference spectrum 1 n/a EPA0650000 Amobarbital - * psy 1 500 mg EPA0700000 Amobarbital sodium - * psy 1 500 mg EPY0001794 Amorolfine Hydrochloride 1 10 mg EPY0001795 Amorolfine for system suitability 1 10 mg EPA0800000 Amoxicillin trihydrate 5 200 mg Follow us on LinkedIn: https://www.linkedin.com/company/lgc-standards-pharma January 2017 and Twitter @LGCStdsPharma Pharmaceutical Lot List - NL European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001521 Amoxicillin trihydrate for performance verification 2 5000 mg EPY0000005 Amphotericin B 5 100 mg EPY0001361 Amphotericin B for microbiological assay 1 100 mg EPY0001014 Amphotericin B for peak identification 2 10 mg EPA1000000 Ampicillin (anhydrous) 5 220 mg EPA1100000 Ampicillin trihydrate 2 150 mg EPY0001244 Amylmetacresol 1 285 mg EPY0001245 Amylmetacresol for peak identification 1 10 mg EPY0001522 Anastrozole 1 100 mg EPY0001531 Anastrozole impurity E 1 10 mg EPY0001870 Andrographis herb HRS 1 2050 mg EPY0001866 Andrographolide 1 15 mg EPY0001753 Anemarrhena rhizome for system suitability HRS 1 150 mg EPY0001386 Angelica dahurica root HRS 1 160 mg EPY0001385 Angelica pubescens root 1 500 mg EPA1200000 Anhydrotetracycline hydrochloride 5 25 mg EPY0001466 Anhydrous Docetaxel 1 15 mg EPA1210000 Antazoline hydrochloride 1 50 mg EPY0001777 Apigenin 7-glucoside 1 25 mg EPY0001465 Apomorphine hydrochloride hemihydrate 1 15 mg EPY0001471 Apomorphine impurity B (morphine sulfate) -* narc 1 40 mg EPY0001825 Aprepitant 1 150 mg EPY0001826 Aprepitant for system suitability 1 15 mg EPY0001154 Aprotinin for system suitability 1 2.7 mg EPA1250000 Aprotinin solution BRP 4 0.5 mL EPA1269000 L-Arabinitol 2 10 mg EPY0000806 Arbutin 2 110 mg EPA1270000 Arginine 4 60 mg EPY0000304 Arginine aspartate 1 20 mg EPA1271000 Arginine hydrochloride 3 60 mg EPY0001649 Aripiprazole 2 170 mg Follow us on LinkedIn: https://www.linkedin.com/company/lgc-standards-pharma January 2017 and Twitter @LGCStdsPharma Pharmaceutical Lot List - NL European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No.
Load more

Recommended publications
  • Asthma/COPD Agents
    Quick Reference Drug List: Asthma/COPD Agents each State Health Plan has compiled a list of available products used to treat this condition. This reference will help identify preferred products, in addition to some P limitations or step-therapies when a product requires a prior authorization. Any non-PDL product will require the trial and failure of two PDL agents be documented on a prior authorization review. Generic products are preferred. Prior Authorizations should be sent to Envolve Pharmacy Solutions: Prior Authorization Phone: 866-399-0928 Prior Authorization Fax: 866-399-0929 MEDICAID DRUG INGREDIENT DOSAGE PDL LIMITS & NAME FORM/STRENGTH STATUS RESTRICTIONS Short Acting Beta Adrenergic Agonists (SABA) Albuterol Albuterol Sulfate Neb Sol: 0.63 mg/3ml, Yes QL: 375ml per 30 Sulfate 1.25mg/3ml, 0.083% day (0.63mg/3ml and (2.5mg/3ml), 0.5% 1/25mg/3ml only); (2.5mg/0.5ml) QL: 12.5 ml per day Syr: 2 mg/5ml (0.083% only); Tabs: 2mg, 4 mg ER Tabs: 4 mg, 8 mg Alupent® Metaproterenol Syr: 10 mg/5 mL Yes QL: 30ml per day Tabs: 10 mg, 20 mg (syrup only) Brethine® Terbutaline Tabs: 2.5 mg, 5mg Yes None ProAir HFA® Albuterol sulfate Aero sol: 90 mcg/act Yes QL: 8.5gm per fill, 17gm per 30 days ProAir Albuterol sulfate Aero sol: 90 mcg/act Yes AL: At least 4 years Respiclick® old up to 18 years old Proventil Albuterol sulfate Aero sol: 90 mcg/act No PA Required HFA® Ventolin Albuterol Sulfate Aero sol: 90 mcg/act Yes QL: 8gm per fill, HFA® 36gm per 30 days Xopenex® Levalbuterol Neb sol: 0.31mg/3ml, No PA Required 0.63mg/3ml, 1.25mg/0.5ml, 1.25mg/3ml
    [Show full text]
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Clinical Policy: Topical Agents: Corticosteroids
    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • An HPLC-DAD Method to Quantify Flavonoids in Sonchus Arvensis and Able to Classify the Plant Parts and Their Geographical Area Through Principal Component Analysis
    separations Article An HPLC-DAD Method to Quantify Flavonoids in Sonchus arvensis and Able to Classify the Plant Parts and Their Geographical Area through Principal Component Analysis Rifki Husnul Khuluk 1 , Amalia Yunita 1, Eti Rohaeti 1,2, Utami Dyah Syafitri 2,3, Roza Linda 4, Lee Wah Lim 5, Toyohide Takeuchi 5 and Mohamad Rafi 1,2,* 1 Departement of Chemistry, Faculty of Mathematics and Natural Science, IPB University, Jalan Tanjung Kampus IPB Dramaga, Bogor 16680, Indonesia; [email protected] (R.H.K.); [email protected] (A.Y.); [email protected] (E.R.) 2 Tropical Biopharmaca Research Center, Research and Community Empowerment Institute, IPB University, Jalan Taman Kencana No. 3 Kampus IPB Taman Kencana, Bogor 16128, Indonesia; [email protected] 3 Department of Statistics, Faculty of Mathematics and Natural Science, IPB University, Jalan Meranti Kampus IPB Dramaga, Bogor 16680, Indonesia 4 Department of Chemistry Education, Faculty of Education, Riau University, Jalan Pekanbaru-Bangkinang KM 12.5 Kampus Bina Widya, Pekanbaru 28293, Indonesia; [email protected] 5 Department of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan; [email protected] (L.W.L.); [email protected] (T.T.) * Correspondence: [email protected]; Tel.: +62-2518624567 Abstract: A simple and efficient method has been developed for the simultaneous determination of eight flavonoids (orientin, hyperoside, rutin, myricetin, luteolin, quercetin, kaempferol, and apigenin) in Sonchus arvensis by high-performance liquid chromatography diode array detector (HPLC-DAD). Citation: Khuluk, R.H.; Yunita, A.; This method was utilized to differentiate S.
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • Highlights of Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gastrointestinal Perforation: Increased risk in patients with certain GI These highlights do not include all the information needed to use disorders; Signs and symptoms may be masked (5.4) ® EMFLAZA safely and effectively. See full prescribing information for • Behavioral and Mood Disturbances: May include euphoria, insomnia, EMFLAZA. mood swings, personality changes, severe depression, and psychosis (5.5) • Effects on Bones: Monitor for decreases in bone mineral density with EMFLAZA® (deflazacort) tablets, for oral use EMFLAZA® (deflazacort) oral suspension chronic use of EMFLAZA (5.6) Initial U.S. Approval: 2017 • Ophthalmic Effects: May include cataracts, infections, and glaucoma; Monitor intraocular pressure if EMFLAZA is continued for more than 6 ---------------------------INDICATIONS AND USAGE--------------------------- weeks (5.7) EMFLAZA is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older (1) • Vaccination: Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids. Administer live- ----------------------DOSAGE AND ADMINISTRATION---------------------- attenuated or live vaccines at least 4 to 6 weeks prior to starting • The recommended once-daily dosage is approximately 0.9 mg/kg/day EMFLAZA (5.8) administered orally (2.2) • Serious Skin Rashes: Discontinue at the first sign of rash, unless the rash is • Discontinue gradually when administered for more than a few
    [Show full text]